Section 33: Disclosure of interest

33. Disclosure of interest (1) Where any member of the Council, Pharmacovigilance Committee or Ethics Committee, or any person related to him by blood or marriage, has a C25A – 19 [Issue 4] Clinical Trials Act financial or other material interest in relation to any matter before the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, that member— (a) shall disclose the nature of the interest at or before the meeting convened to discuss the matter; and (b) shall not take part in any deliberations of the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, relating to the matter. (2) Where any member of the Council, Pharmacovigilance Committee or Ethics Committee has or acquires any financial interest in any clinical trial in Mauritius or elsewhere, he shall inform the Council, Pharmacovigilance Committee or Ethics Committee, as the case may be, in writing, of such interest.